Close menu




April 15th, 2021 | 07:15 CEST

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments
Photo credits: pixabay.com

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

time to read: 4 minutes | Author: Stefan Feulner
ISIN: US01609W1027 , SG1Q02920318 , NL0015436031

Table of contents:


    CureVac - The pressure is mounting

    The disputes over AstraZeneca's vaccine are followed by Johnson & Johnson's suspension of the drug's supply. There seems to be no end to the German vaccination disaster. Now the SPD health expert and regular guest on the show "Markus Lanz," Karl Lauterbach, is speaking out. This time not, as usual, to admonish, but to demand. According to a Spiegel interview, he is demanding that Germany prepare an emergency approval for CureVac. If the vaccine works as well as BioNTech or Moderna, it should be "approved and vaccinated as quickly as possible." Initially, the Tübingen-based Company planned EU approval of the CureVac vaccine for early June.

    An advanced study is currently ongoing in Europe and Latin America with around 35,000 participants on the vaccine's effectiveness. From a chart perspective, the Tübingen share was able to break out of the corridor formed since the beginning of March at around EUR 80 yesterday following the statements. The next price target is currently EUR 92.50. It would not be surprising if the share targeted its all-time high of EUR 109.54 in the next few weeks due to the upcoming news flow.

    The Place Holdings - Unique mix

    Corona threatens the extinction of the city centers in Germany. New concepts are needed. When it comes to visions, it is worth taking a look at Asia, as is the case with many things. Here, The Place Investment Group, a billion-dollar company from China, has been operating its key project "The Place" since 2006, consisting of two office buildings, a high-quality retail center and Asia's largest sky screen, measuring 250 meters by 30 meters. With its mix of fashion, relaxation, entertainment and culture, "The Place" forms the basis for developing new retail concepts as an omnichannel real estate platform. With The Place Holdings listed on the Singapore Stock Exchange since 2016 and in Frankfurt since the beginning of the year, the business model is now to be further expanded and refined.

    Although major cities are up to date in terms of modern lifestyle, much of China is still in a construction phase in terms of project and urban development. Here, the Company aims to uniquely combine the three business pillars of real estate development and management, cultural tourism and integrated media. The Company's goal is to purchase underutilized assets to revitalize them with innovative management concepts from advertising, shopping and entertainment.

    With EUR 46 million currently in the bank, the debt-free company has already acquired three acquisitions with different objectives since 2019. In April 2019, The Place Holdings secured a freehold property previously known as Realty Centre for the equivalent of EUR 93.0 million. Here, management is speculating on the entitlement to
    Bonus property ratios of between 25% to 30% if a change of use occurs under the Central Business District (CBD) Incentive Scheme. In November 2020, the subscription of an 80% equity stake in Tianjie Yuntai Wanrun Property Development, which owns approximately 270,500 square meters of commercial space in the southeast of Mount Yuntai. The area around the Wanrun Property has seen significant development and the Group is currently in the midst of the land zoning change process. Doing so will increase gross floor area and provide access to a broader group of interested buyers.

    A strategically significant step for the future was taken through the strategic partnership with MCC Land, an established developer in Singapore. Thus, a 20% stake was taken in MCC Land's mixed development project adjacent to the Tanah Merah MRT interchange. The mixed development site has a land area of 8,880 square meters and can provide 265 condominiums and 2,000 square meters of commercial space. The Place Holdings Limited operates in an extreme growth market and is traded in Germany and its home exchange in Singapore. The Place Holdings has a market capitalization of EUR 485 million. With the rise in property price levels in the emerging Chinese housing market, investors can directly benefit in the long run.

    Alibaba - Painful cuts

    As expected, the Chinese government's battle against Alibaba is entering the next round. The record fine of EUR 2.3 billion against the Company last week was somewhat symbolic and is easy to get over due to the profit of EUR 10 billion in the past three months. More challenging now are the latest pinpricks against the subsidiary Ant Group, including the payment service Alipay. Thus, regulators have ordered a restructuring of the financial Company. Ant Group must transform itself into a financial holding company, subject to the supervisory authorities like a bank. As a result, it must meet stricter requirements and hold more liquidity.

    The Company would have to accept the authorities' stricter supervision and stop "illegal" activities in loans, insurance and asset management. High financial charges and risks of its financial services must be better controlled, the authorities demand. These measures are causing the Company's value, which was worth USD 280 billion when it went public, to fall tremendously. Due to the uncertainties regarding the valuation and possible further burdensome measures, we do not recommend investing in Alibaba for the time being.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read